NewAmsterdam Pharma Company (NAMS) AI Stock Analysis

• Market Cap: $2.39B
• Dividend Yield: N/A
• Average Volume (3M): 1.10M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.64
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 68
• Sector: Healthcare
• Sector Strength: 71
• Industry: Biotechnology
• EPS (TTM): -2.60
• Shares Outstanding: 109,817,810
• 10 Day Avg. Volume: 1,071,875
• 30 Day Avg. Volume: 1,104,990
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 79.94
• Price to Cash Flow (P/CF): -52.40
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $43.43
• Price Target Upside: 99.59% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9

NewAmsterdam Pharma's stock is bolstered by strong technical momentum and positive corporate events, including promising trial results and a successful capital raise. However, financial performance remains a challenge due to ongoing losses and cash flow issues. The lack of profitability and low valuation score are key risks but are typical of biotech firms focused on R&D. The company is well-positioned for future growth if it can leverage its strong balance sheet and recent achievements towards commercial success.

Positive Factors

Clinical Trial Success

Recent positive data from both Ph.3 BROADWAY (monotherapy) & Ph.3 TANDEM (fixed-dose combination) trials demonstrated obi's robust efficacy in LDL-C reduction with a placebo-like safety profile.

Financial Position

The company is well-funded with cash of ~$834MM for operations beyond the PREVAIL CVOT readout and potential obi commercial launch.

Strategic Developments

NewAmsterdam (NAMS) delivered a compelling 2025 strategic roadmap that significantly derisks their path to commercialization of lead asset obicetrapib (obi), reinforcing the view that obi could transform the future cardiovascular disease treatment landscape, if approved.

Negative Factors

R&D Expenses

Price target moves to $42 from $46 to reflect model updates with higher than expected R&D in 2025.

Timeline for Data

The next significant data catalyst is not expected until PREVAIL CVOT.

NewAmsterdam Pharma Company Business Overview & Revenue Model

Company Description

NewAmsterdam Pharma Company (NAMS) is a clinical-stage biopharmaceutical company dedicated to the research, development, and commercialization of transformative therapies. The company primarily focuses on addressing cardiovascular and metabolic diseases, with its flagship product being an innovative oral small molecule therapy aimed at reducing cardiovascular risk in patients with high cholesterol levels. Leveraging cutting-edge science and strategic partnerships, NAMS seeks to bring novel treatment options to patients worldwide.

How the Company Makes Money

NewAmsterdam Pharma Company (NAMS) generates revenue through a combination of product sales, strategic partnerships, and licensing agreements. The company's primary revenue stream is anticipated to come from the commercialization of its lead product candidate, which is currently in clinical trials. Upon successful approval by regulatory authorities, NAMS plans to market and sell this therapy to healthcare providers and patients, thereby generating sales revenue. Additionally, NAMS engages in partnerships with other pharmaceutical companies and research institutions, which may involve collaborative research and development efforts, resulting in milestone payments and royalties. These significant partnerships not only provide financial support but also enhance the company's access to cutting-edge research and development capabilities, further contributing to its revenue potential.

NewAmsterdam Pharma Company Financial Statement Overview

Summary

NewAmsterdam Pharma shows strong revenue growth but struggles with profitability due to high R&D expenses. The balance sheet is robust with low leverage, though cash flow is a concern due to consistent negative operating cash flow. Overall, the company needs to achieve profitability for long-term sustainability.

Income Statement

The company's revenue has shown significant volatility with periods of growth and decline. The gross profit margin is 100% due to no cost of goods sold, but the net profit margin is low due to high operating expenses. EBIT and EBITDA margins are negative, indicating operational challenges. Revenue growth from 2023 to 2024 is strong, but the company has not achieved profitability.

Balance Sheet

The company maintains a strong equity position with an equity ratio of 87.6%, indicating low leverage. Debt-to-equity is minimal at 0.06, suggesting low financial risk. However, the company has reported consecutive net losses, impacting return on equity, which remains negative.

Cash Flow

Operating cash flow is consistently negative, highlighting cash burn issues typical in the biotechnology industry. Free cash flow growth is negative, indicating increased outflows. However, ample financing cash flow suggests the company is able to raise capital successfully, mitigating immediate liquidity concerns.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
45.56M	12.76M	95.91M	0.00	0.00
	Gross Profit
45.56M	12.76M	95.91M	0.00	0.00
	EBIT
-176.29M	-165.73M	-3.32M	-30.73M	-5.43M
	EBITDA
-241.49M	-176.86M	-3.31M	-30.73M	-5.43M
	Net Income Common Stockholders
-241.60M	-176.94M	-21.14M	-36.71M	-5.75M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
834.19M	340.45M	438.52M	53.09M	7.86M
	Total Assets
864.62M	347.10M	531.58M	59.78M	9.23M
	Total Debt
448.00K	60.00K	118.00K	164.00K	11.65M
	Net Debt
-771.29M	-340.39M	-438.40M	-52.93M	3.79M
	Total Liabilities
107.12M	58.70M	47.06M	9.99M	12.81M
	Stockholders Equity
757.50M	288.39M	484.52M	49.79M	-3.58M
Cash Flow		Free Cash Flow
-159.24M	-141.24M	7.96M	-25.18M	-5.98M
	Operating Cash Flow
-158.56M	-141.22M	7.97M	-25.16M	-5.97M
	Investing Cash Flow
-62.85M	-24.00K	715.00K	-20.00K	-13.00K
	Financing Cash Flow
659.51M	8.91M	375.18M	68.99M	11.32M

NewAmsterdam Pharma Company Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 21.76
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NAMS, the sentiment is Negative. The current price of 21.76 is below the 20-day moving average (MA) of 23.07, above the 50-day MA of 21.73, and above the 200-day MA of 20.13, indicating a neutral trend. The MACD of 0.35 indicates Positive momentum. The RSI at 43.73 is Neutral, neither overbought nor oversold. The STOCH value of 14.15 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NAMS.

NewAmsterdam Pharma Company Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AKRO	60 Neutral	$3.40B	―	-39.22%	―	―	-31.37%
NAMS	59 Neutral	$2.39B	―	-61.35%	―	―	―
MDGL	54 Neutral	$7.24B	―	-80.35%	―	―	-10.89%
Sector *	49 Neutral	$6.85B	0.81	-52.91%	2.50%	19.94%	1.20%
AMRN	42 Neutral	$181.18M	―	-15.79%	―	-25.86%	-37.14%
VKTX	42 Neutral	$2.88B	―	-17.90%	―	―	-10.27%
ESPR	40 Underperform	$296.77M	―	23.44%	―	185.66%	89.22%

NewAmsterdam Pharma Company Corporate Events

NewAmsterdam Pharma Achieves Key Milestones in 2024

NewAmsterdam Pharma reported significant achievements in 2024 with positive results from three pivotal Phase 3 trials for obicetrapib, aimed at lowering LDL-C and reducing cardiovascular risks. The company plans to further advance its clinical trials in 2025 and focus on commercial readiness for potential launches in the U.S. and Europe, supported by a strong financial position.